ES2246149B1 - Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. - Google Patents
Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. Download PDFInfo
- Publication number
- ES2246149B1 ES2246149B1 ES200401729A ES200401729A ES2246149B1 ES 2246149 B1 ES2246149 B1 ES 2246149B1 ES 200401729 A ES200401729 A ES 200401729A ES 200401729 A ES200401729 A ES 200401729A ES 2246149 B1 ES2246149 B1 ES 2246149B1
- Authority
- ES
- Spain
- Prior art keywords
- omeprazole
- magnesium salt
- water
- starting
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007787 solid Substances 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000003839 salts Chemical class 0.000 title claims description 14
- 229960000381 omeprazole Drugs 0.000 claims abstract description 108
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000002904 solvent Substances 0.000 claims abstract description 33
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 229960003117 omeprazole magnesium Drugs 0.000 claims description 14
- 239000006184 cosolvent Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 8
- 238000004807 desolvation Methods 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000007614 solvation Methods 0.000 abstract description 3
- 230000003287 optical effect Effects 0.000 abstract description 2
- 238000012776 robust process Methods 0.000 abstract 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 8
- 150000003457 sulfones Chemical class 0.000 description 6
- 239000012535 impurity Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 238000005169 Debye-Scherrer Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010057969 Reflux gastritis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- VWEMSUCCUQSLME-UHFFFAOYSA-N alkofanone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C(C=1C=CC=CC=1)CC(=O)C1=CC=CC=C1 VWEMSUCCUQSLME-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- TZNULHNPXDZANP-UHFFFAOYSA-N magnesium;methanol Chemical compound [Mg].OC TZNULHNPXDZANP-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401729A ES2246149B1 (es) | 2004-07-02 | 2004-07-02 | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
| MXPA06014736A MXPA06014736A (es) | 2004-07-02 | 2005-06-29 | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
| KR1020077000063A KR101290035B1 (ko) | 2004-07-02 | 2005-06-29 | （ｓ）―오메프라졸 마그네슘염의 고체형태 및 그 제조과정 |
| EP05760736A EP1765807B1 (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (s)-omeprazole and processes for their preparation |
| CN2005800215619A CN1976923B (zh) | 2004-07-02 | 2005-06-29 | (s)-奥美拉唑镁盐的固体形式及其制备方法 |
| ZA200700865A ZA200700865B (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation |
| HR20090211T HRP20090211T1 (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (s)-omeprazole and processes for their preparation |
| DK05760736T DK1765807T3 (da) | 2004-07-02 | 2005-06-29 | Faste former af magnesiumsaltet af (S)-omeprazol og fremgangsmåder til fremstilling heraf |
| US11/571,564 US7902370B2 (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of S-omeprazole and processes for their preparation |
| JP2007519776A JP5575366B2 (ja) | 2004-07-02 | 2005-06-29 | （ｓ）−オメプラゾールのマグネシウム塩の固形形態とその製造方法 |
| ES05760736T ES2323319T3 (es) | 2004-07-02 | 2005-06-29 | Formas solidas de la sal magnesica de (s)-omeprazol y procedimiento para su preparacion. |
| NZ552458A NZ552458A (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation |
| AT05760736T ATE425975T1 (de) | 2004-07-02 | 2005-06-29 | Feste formen des magnesiumsalzes von (s)- omeprazol und verfahren zu deren herstellung |
| PT05760736T PT1765807E (pt) | 2004-07-02 | 2005-06-29 | Formas sólidas do sal de magnésio de (s)-omeprazole e processos para a sua preparação |
| DE602005013382T DE602005013382D1 (de) | 2004-07-02 | 2005-06-29 | Feste formen des magnesiumsalzes von (s)-omeprazol und verfahren zu deren herstellung |
| AU2005259205A AU2005259205B2 (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation |
| CA2570559A CA2570559C (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (s)-omeprazole and processes for their preparation |
| PCT/EP2005/053062 WO2006003163A1 (en) | 2004-07-02 | 2005-06-29 | Solid forms of the magnesium salt of (s)-omeprazole and processes for their preparation |
| NO20070635A NO20070635L (no) | 2004-07-02 | 2007-02-02 | Faste former av magnesiumsalt av S-omeprazol og fremgangsmater for deres fremstilling |
| CY20091100473T CY1109048T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2004-07-02 | 2009-04-29 | |
| JP2014088458A JP2014169302A (ja) | 2004-07-02 | 2014-04-22 | （ｓ）−オメプラゾールのマグネシウム塩の固形形態とその製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401729A ES2246149B1 (es) | 2004-07-02 | 2004-07-02 | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2246149A1 ES2246149A1 (es) | 2006-02-01 |
| ES2246149B1 true ES2246149B1 (es) | 2007-06-01 |
Family
ID=34972307
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200401729A Expired - Fee Related ES2246149B1 (es) | 2004-07-02 | 2004-07-02 | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
| ES05760736T Expired - Lifetime ES2323319T3 (es) | 2004-07-02 | 2005-06-29 | Formas solidas de la sal magnesica de (s)-omeprazol y procedimiento para su preparacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05760736T Expired - Lifetime ES2323319T3 (es) | 2004-07-02 | 2005-06-29 | Formas solidas de la sal magnesica de (s)-omeprazol y procedimiento para su preparacion. |
Country Status (19)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246149B1 (es) * | 2004-07-02 | 2007-06-01 | Esteve Quimica, S.A. | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
| FR2920428B1 (fr) * | 2007-08-29 | 2012-06-15 | Univ Rouen | Procede de dedoublement de sels de l'omeprazole |
| EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
| CN103044400A (zh) * | 2012-12-21 | 2013-04-17 | 北京华禧联合科技发展有限公司 | 埃索美拉唑镁盐及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998028294A1 (en) * | 1996-12-20 | 1998-07-02 | Astra Aktiebolag | A novel compound form |
| EP1375497A1 (en) * | 2002-05-17 | 2004-01-02 | Bernard Charles Sherman | Magnesium salt of s-omeprazole |
| WO2004046134A2 (en) * | 2002-11-18 | 2004-06-03 | Dr. Reddy's Laboratories Limited | Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation |
| WO2004089935A1 (en) * | 2003-04-10 | 2004-10-21 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| HUT75775A (en) * | 1994-07-08 | 1997-05-28 | Astra Ab | Medicament with multiple unit tablated dosage form containing omeprazole |
| SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
| SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| US6326384B1 (en) * | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| SI20974A (sl) * | 1999-08-26 | 2003-02-28 | Aaipharma, Inc. | Alkoksi substituirane benzimidazolne spojine, farmacevtski pripravki, ki jih vsebujejo ter metode za njihovo uporabo |
| US6312712B1 (en) * | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| CN1437593A (zh) | 2000-05-15 | 2003-08-20 | 兰贝克赛实验室有限公司 | 新颖的无定形奥美拉唑盐 |
| CA2775616C (en) * | 2000-08-04 | 2013-09-17 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and application thereof |
| SI20875A (sl) * | 2001-04-25 | 2002-10-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristalna oblika omeprazola |
| WO2003089408A2 (en) * | 2002-04-22 | 2003-10-30 | Sun Pharmaceutical Industries Limited | Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts |
| US6894066B2 (en) * | 2002-05-09 | 2005-05-17 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
| US7612098B2 (en) * | 2002-08-30 | 2009-11-03 | Dr. Reddy's Laboratories Limited | Amorphous hydrous esomeprazole magnesium |
| CN1728997A (zh) * | 2002-10-22 | 2006-02-01 | 兰贝克赛实验室有限公司 | (es)奥美拉唑的无定形盐 |
| ES2246149B1 (es) * | 2004-07-02 | 2007-06-01 | Esteve Quimica, S.A. | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
-
2004
- 2004-07-02 ES ES200401729A patent/ES2246149B1/es not_active Expired - Fee Related
-
2005
- 2005-06-29 NZ NZ552458A patent/NZ552458A/en not_active IP Right Cessation
- 2005-06-29 DE DE602005013382T patent/DE602005013382D1/de not_active Expired - Lifetime
- 2005-06-29 ZA ZA200700865A patent/ZA200700865B/xx unknown
- 2005-06-29 HR HR20090211T patent/HRP20090211T1/xx unknown
- 2005-06-29 AT AT05760736T patent/ATE425975T1/de active
- 2005-06-29 AU AU2005259205A patent/AU2005259205B2/en not_active Ceased
- 2005-06-29 MX MXPA06014736A patent/MXPA06014736A/es active IP Right Grant
- 2005-06-29 CN CN2005800215619A patent/CN1976923B/zh not_active Expired - Fee Related
- 2005-06-29 WO PCT/EP2005/053062 patent/WO2006003163A1/en active Application Filing
- 2005-06-29 EP EP05760736A patent/EP1765807B1/en not_active Expired - Lifetime
- 2005-06-29 US US11/571,564 patent/US7902370B2/en not_active Expired - Fee Related
- 2005-06-29 CA CA2570559A patent/CA2570559C/en not_active Expired - Fee Related
- 2005-06-29 DK DK05760736T patent/DK1765807T3/da active
- 2005-06-29 PT PT05760736T patent/PT1765807E/pt unknown
- 2005-06-29 JP JP2007519776A patent/JP5575366B2/ja not_active Expired - Fee Related
- 2005-06-29 ES ES05760736T patent/ES2323319T3/es not_active Expired - Lifetime
- 2005-06-29 KR KR1020077000063A patent/KR101290035B1/ko not_active Expired - Fee Related
-
2007
- 2007-02-02 NO NO20070635A patent/NO20070635L/no not_active Application Discontinuation
-
2009
- 2009-04-29 CY CY20091100473T patent/CY1109048T1/el unknown
-
2014
- 2014-04-22 JP JP2014088458A patent/JP2014169302A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998028294A1 (en) * | 1996-12-20 | 1998-07-02 | Astra Aktiebolag | A novel compound form |
| EP1375497A1 (en) * | 2002-05-17 | 2004-01-02 | Bernard Charles Sherman | Magnesium salt of s-omeprazole |
| WO2004046134A2 (en) * | 2002-11-18 | 2004-06-03 | Dr. Reddy's Laboratories Limited | Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation |
| WO2004089935A1 (en) * | 2003-04-10 | 2004-10-21 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1765807B1 (en) | 2009-03-18 |
| CA2570559A1 (en) | 2006-01-12 |
| US7902370B2 (en) | 2011-03-08 |
| NZ552458A (en) | 2010-07-30 |
| MXPA06014736A (es) | 2007-06-25 |
| KR101290035B1 (ko) | 2013-07-30 |
| DK1765807T3 (da) | 2009-06-08 |
| JP2014169302A (ja) | 2014-09-18 |
| CN1976923B (zh) | 2011-08-24 |
| CN1976923A (zh) | 2007-06-06 |
| JP2008505160A (ja) | 2008-02-21 |
| WO2006003163A1 (en) | 2006-01-12 |
| AU2005259205B2 (en) | 2011-01-27 |
| DE602005013382D1 (de) | 2009-04-30 |
| US20070249684A1 (en) | 2007-10-25 |
| ZA200700865B (en) | 2009-09-30 |
| KR20070031992A (ko) | 2007-03-20 |
| AU2005259205A1 (en) | 2006-01-12 |
| CA2570559C (en) | 2012-08-28 |
| ATE425975T1 (de) | 2009-04-15 |
| CY1109048T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2014-07-02 |
| HRP20090211T1 (en) | 2009-05-31 |
| PT1765807E (pt) | 2009-04-13 |
| ES2323319T3 (es) | 2009-07-13 |
| EP1765807A1 (en) | 2007-03-28 |
| ES2246149A1 (es) | 2006-02-01 |
| NO20070635L (no) | 2007-03-20 |
| JP5575366B2 (ja) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2318850T3 (es) | Un procedimiento para la purificacion optica de derivados de bencimidazol enantiomericamente enriquecidos. | |
| ES2367419T3 (es) | Métodos de producción de cristales. | |
| ES2300265T3 (es) | Forma cristalina de (r)-2-(((3-metil-4-(2,2,2-trifluoroetoxi)-2-piridinil)metil)sulfinil)-1h-bencimidazol. | |
| PT2318390E (pt) | Compostos de pirrole | |
| CN105358547A (zh) | 作为强效rock1和rock2抑制剂的苯基吡唑衍生物 | |
| ES2375298T3 (es) | Procedimiento para preparar derivados de sulfóxido sustituidos. | |
| AU2021381516A1 (en) | Integrin inhibitor and uses thereof | |
| BRPI0310118B1 (pt) | processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila | |
| ES2246149B1 (es) | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. | |
| ES2523921T3 (es) | Procedimiento de preparación de la sal sódica de esomeprazol | |
| IL179813A (en) | S-tenatoprazole sodium monohydrate salt, solutions and compositions containing same, use thereof in manufacture of a medicament and methods of preparation thereof | |
| WO2007017244A2 (en) | A PROCESS FOR THE PURIFICATION OF SUBSTITUTED 2-(2-PYRIDYLMETHYL)SULFINYL-lH-BENZIMIDAZOLE COMPOUNDS BY PRECIPITATION IN THE PRESENCE OF A QUATERNARY AMMONIUM SALT | |
| CN103012369B (zh) | 兰索拉唑n晶型及其制备方法和应用 | |
| WO2025124537A1 (en) | Integrin inhibitor and uses thereof | |
| ES2294931B1 (es) | Sal de l-arginina de esomeprazol, procedimiento de preparacion y composiciones farmaceuticas que la comprenden. | |
| KR20130063762A (ko) | 신규 에스라베프라졸, 이의 알칼리금속 및 알칼리토금속염 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20060201 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2246149B1 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180809 |